医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

2024年05月21日 PM06:30
このエントリーをはてなブックマークに追加


 

HANGZHOU, China

HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic monkeys has been accepted for a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando, FL. The abstract also will be published on the website of the ADA’s journal Diabetes.

“We are very excited to introduce our unique lipid nanoparticle (LNP)-mRNA complex, HFG1, to the thousands of clinicians and researchers attending this year’s Scientific Sessions from around the world,” said HighField CEO and Scientific Founder Yuhong Xu, Ph.D. “The components of HFG1’s LNP complex were designed to provide consistent expression of a GLP-1R agonist for diabetes and weight loss. We believe HFG1 will require far fewer injections than existing GLP-1 products while providing steady-state agonist activity.”

Abstract Title:

 

Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys. (Poster presentation number 1860-LB in category 12-B Clinical Therapeutics-Incretin-Based Therapies).

 

 

Presenter:

Dr. Yuhong Xu, HighField CEO

 

 

Presentation:

 

Saturday, June 22, 2024, 12:30 pm – 1:30 pm EDT (The poster will be displayed Saturday, Sunday and Monday in the Poster Hall; and at a Networking Reception Friday evening.)

About HighField Biopharmaceuticals

HighField is a clinical stage company focused on novel applications of liposome constructs to disrupt existing immuno-oncology and other disease technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers and lipid therapeutics for gene delivery and gene therapy. For more information visit https://highfield.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521146324/en/

CONTACT

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net

425-306-8716

Business Development Contact:

Donald Wyatt

HighField Biopharmaceuticals

dwyatt@hf-biopharm.com

206-356-8196

同じカテゴリーの記事 

  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
  • ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命
  • ICH and CDISC Collaborate to Support the Maintenance and Governance Process for ICH M11 Controlled Terminology